Premium
RITUXIMAB SC AND IV PLUS CHOP SHOW SIMILAR EFFICACY AND SAFETY IN THE RANDOMISED MABEASE STUDY IN FIRST‐LINE DLBCL
Author(s) -
Lugtenburg P.J.,
Avivi I.,
Berenschot H.W.,
Ilhan O.,
Marolleau J.P.,
Nagler A.,
Rueda A.,
Tani M.,
Turgut M.,
Osborne S.A.,
Smith R.B.,
Pfreundschuh M.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_46
Subject(s) - rituximab , medicine , chop , adverse effect , cyclophosphamide , gastroenterology , vincristine , clinical endpoint , chemotherapy , lymphoma , randomized controlled trial